EU and CEPI vaccine funds AUF1 relays Hauser critique

Jun 1

AUF1 criticizes EU financing of Ebola vaccine development while saying the Commission considers Europe's Bundibugyo-virus risk very low. It reports €73.7 million for CEPI, then a CEPI commitment of up to US$50 million for Moderna's experimental mRNA candidate, with first human tests already underway. It attributes to FPÖ MEP Gerald Hauser the view that this is another pharmaceutical business at European taxpayers' expense. The passage reports commitments and trials, not vaccine efficacy, approval or proof of misuse, and does not date the commitments.

AUF1 reports CEPI pledging up to US$50 million for Moderna's experimental mRNA vaccine against Bundibugyo ebolavirus and says first human tests are underway by the October broadcast. It presents this within criticism of EU–CEPI funding and attributes taxpayer-cost objections to Gerald Hauser. No efficacy, approval or completed trial outcome is reported.